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introduction: We describe the etiology, MRI findings, and growth patterns in girls who 
had presented with signs of precocious puberty (PP), i.e., premature breast develop-
ment or early menarche. Special attention was paid to the diagnostic findings in 6- to 
8-year-olds.
Materials and methods: We reviewed the medical records of 149 girls (aged 0.7–
10.3 years) who had been evaluated for PP in the Helsinki University Hospital between 
2001 and 2014.
results: In 6- to 8-year-old girls, PP was most frequently caused by idiopathic gonad-
otropin-releasing hormone (GnRH)-dependent PP (60%) and premature thelarche (PT; 
39%). The former subgroup grew faster (8.7 ± 2.0 cm/year, n = 58) than the girls with PT 
(7.0 ± 1.1 cm/year, n = 32) (P < 0.001), and the best discrimination for GnRH-dependent 
PP was achieved with a growth velocity cut-off value of 7.0 cm/year (sensitivity 92% and 
specificity 58%) [area under the curve 0.82, 95% confidence interval (CI) 0.73–0.91, 
P  <  0.001]. Among asymptomatic and previously healthy 6- to 8-year-old girls with 
GnRH-dependent PP, one (1.7%, 95% CI 0.3–9.7%) had a pathological brain MRI find-
ing requiring surgical intervention (craniopharyngioma). In girls younger than 3 years, the 
most frequent cause of breast development was PT, and, in 3- to 6-year-olds, GnRH-
dependent PP.
conclusion: In 6- to 8-year-old girls, analysis of growth velocity is helpful in differentiat-
ing between PT and GnRH-dependent PP. Although the frequency of clinically relevant 
intracranial findings in previously healthy, asymptomatic 6- to 8-year-old girls was low, 
they can present without any signs or symptoms, which favors routine MRI imaging also 
in this age group.
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inTrODUcTiOn
During the last 50 years, there has been a continuing downward 
trend toward an earlier timing of puberty, evidenced in girls by 
an earlier mean age of breast development and, to lesser extent, 
menarche (1, 2). In girls, puberty is considered to be precocious 
when it occurs before the age of 8 years (3–5), and when preco-
cious puberty (PP) manifests secondary to the activation of the 
hypothalamic–pituitary–gonadal (HPG) axis, the condition 
is considered to be gonadotropin-releasing hormone (GnRH) 
dependent. However, secondary sexual characteristics can occur 
without the activation of the HPG axis. For example, the premature 
appearance of glandular breast tissue or pubic hair can be caused 
by benign variants premature thelarche (PT) or adrenarche, or by 
pathologic GnRH-independent PP such as in McCune–Albright 
syndrome or in congenital adrenal hyperplasia (6).
GnRH-dependent PP is a relatively rare condition showing 
an incidence of approximately 0.2% (7), and in girls approxi-
mately 95% of the cases are idiopathic (8–10). In the remaining 
proportion, the premature activation of the HPG axis is caused 
by an abnormality in the central nervous system (CNS), which 
emphasizes the need to identify these subjects as early as possible. 
At the same time, incidental findings in brain MRI are relatively 
common and their role in GnRH-dependent PP are not always 
clear (10, 11). Young age is a major predictor of CNS pathology, 
whereas the prevalence of pathologic GnRH-dependent PP 
declines with age being approximately 2% in girls above 6 years 
according to previous reports (8, 10). Therefore, the Lawson 
Wilkins Pediatric Endocrine Society (LWPES) and European 
Society of Pediatric Endocrinology (ESPE) recommended that 
in girls with GnRH-dependent PP, a brain MRI should be per-
formed in all subjects less than 6 years of age; whereas in girls 
aged 6–8 years, brain MRI may be reserved to those who show 
a rapid progression of puberty or neurologic signs or symptoms 
(12). The suggested guideline has been supported by some studies 
(10, 13, 14), whereas others have questioned it, and currently no 
consensus or evidence-based criteria for brain imaging exist for 
6- to 8-year-old girls (9, 11, 12).
The prevalence of PT has increased in girls younger than 
8 years without a parallel increase in estradiol or gonadotropin 
levels (15, 16). Thus, identifying girls with PT from those with 
GnRH-dependent PP may be challenging especially among the 
younger girls (17, 18). Increased growth velocity serves as a good 
indirect marker of estrogen activity (through GH/IGF-1 axis 
activation) (19), but its clinical use in the differential diagnosis of 
PP is, still, an open-ended question.
The aim of this study was to report the etiology of PP in a 
tertiary center with special focus on the imaging findings of girls 
with GnRH-dependent PP who were diagnosed between the ages 
of 6 and 8 years. In addition, we evaluated if growth velocity could 
effectively differentiate between PT and GnRH-dependent PP.
MaTerials anD MeThODs
An ICD-10 code-based inquiry was performed to the electronic 
patient records to identify patients who were evaluated for signs 
of PP in the Pediatric Endocrine Outpatient Clinic of Helsinki 
University Hospital (HUH) between 2001 and 2014 (Figure 1). 
The following ICD-10 codes were used: E22.80, E28, E28.8, E28.9, 
E29, E29.0, E29.8, E29.9, E30, E30.1, E30.8, E30.9, and Q78.1. 
The inquiry resulted in 856 patients. Of them, 149 girls fulfilled 
the eligibility criteria of PP: clinical signs of puberty defined 
as Tanner breast stage 2 before age 8 or menarche at the age of 
10.3 years or younger (i.e., the mean −3 SD of healthy Finnish 
girls) (3, 5). The ethnicities of the girls were as follows: 126 (85%) 
Caucasian, 12 (8%) African, 5 (3%) Asian, 4 (3%) Asian-Chinese, 
and 2 (1%) Hispanic. Subsequently, the girls were categorized 
into six diagnostic subgroups based on the hormonal, clinical, 
and imagining findings: PT, early menarche, isolated menarche, 
GnRH-independent PP, idiopathic GnRH-dependent PP, and 
pathologic GnRH-dependent PP (20) (Table 1; the cut-off lev-
els of gonadotropins are provided in the footnote). These girls 
formed the population that was used to describe the etiology of PP 
(Figure 1A). Ten girls were previously diagnosed with a disease 
known to predispose to PP (Table S1 in Supplementary Material), 
and the remaining girls (n = 139) without a known predisposing 
disease were included in the further analysis (Figure  1A). Of 
them, subjects aged 6–8 years (n = 96) were analyzed as a separate 
subgroup (Figure 1B). Since the focus of the study was in the girls 
with PP, 14 boys with PP, although identified by the inquiry, were 
excluded from the series (Figure 1A).
The family history of PP was considered positive if a first degree 
relative had had Tanner breast stage 2 before the age of 8 years or 
menarche before the age of 11 years or if the father reported a very 
early timing of puberty. The information was available in all girls and 
it was assessed by a pediatric endocrinologist. Gonadotropin and 
estradiol levels were obtained and measured as described before (22) 
and were available as follows: LH in 143 (96%), FSH in 142 (95%), 
GnRH stimulation test in 120 (81%), and estradiol in 136 (91%).
Growth data were collected in girls older than 3 years and were 
available in 120 (97%) girls (60 with idiopathic GnRH-dependent 
PP, 39 with PT, 11 with pathologic GnRH-dependent PP, 9 with 
early or isolated menarche, and one with GnRH-independent 
PP). Height and weight were measured by trained nurses in 
maternity hospitals, child welfare clinics, school health care, and 
the university hospital endocrinology clinic as described previ-
ously in detail (23). First, the growth curves were visually assessed 
to exclude obvious measuring errors. Then the growth preceding 
the initial evaluation of PP was modeled by determining growth 
between the initial evaluation and the point 6–24 months before 
the initial evaluation. Growth velocity and an annual change 
in height SDS between the two time points were calculated. In 
subjects with annual change in height SDS exceeding +0.3 SD, the 
age at pubertal take-off (i.e., the nearest point in the growth curve 
that precedes the increase in growth velocity) was identified (24). 
Finally, weight-for-height and BMI values were used to describe 
weight progression (25, 26).
This study was approved by the HUH and the ethics commit-
tee for gynecology and obstetrics, pediatrics, and psychiatry of 
HUH.
statistical analyses
The data are presented with number (percentage) or mean ± SD. 
SPSS statistical software version 22.0 (SPSS, Chicago, IL, USA) 
FigUre 1 | (a) Enrollment and outcomes of 149 girls with precocious puberty (PP). (B) Underlying causes of PP and brain MRI findings in 96 girls aged 6–8 years. 
aICD-10 codes: E22.80, E28, E28.8, E28.9, E29, E29.0, E29.8, E29.9, E30, E30.1, E30.8, E30.9, and Q78.1. bPineal cyst. cCraniopharyngioma. †Girls aged 
6–8 years without a disease that predisposes to PP.
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was used in statistical analyses. Between-group comparisons 
were performed with T- and chi-square-test, and Spearman’s rank 
correlation was used in correlation analysis. In 6- to 8-year-old 
girls, linear regression analysis was used in describing the changes 
in number of subjects with PT during the study period, whereas 
logistic regression analysis was used to study the associations of 
clinical measurements with the odds of GnRH-dependent PP. 
Age is a known contributor to the onset of puberty (8); thus, the 
logistic regression analyses were run univariate and adjusted for 
age. The results are shown as odds ratios and 95% confidence 
intervals (CIs). In addition, the diagnostic performance of growth 
velocity in the differential diagnostics between GnRH-dependent 
FigUre 2 | The distribution of causes that underlie precocious puberty (PP) 
in girls aged 0.7–8 years.
TaBle 1 | Classification of girls presenting with signs of precocious puberty.
Diagnosis criteria
Premature thelarche B2–5 less than 8 years of age and prepubertal LHa
Early menarche Menarche at the age of 10.3 years or younger and 
B2 or more
Isolated menarche As above, but B1
GnRH-independent 
precocious puberty








As above, plus an abnormal brain MRI finding
aPeak serum LH ≤ 5 IU/L in a GnRH stimulation test or basal serum LH < 0.3 IU/L.
bPeak serum LH > 5 IU/L in a GnRH stimulation test or basal serum LH ≥ 0.3 IU/L. In 
girls younger than 3 years, documented progression of puberty or an abnormal brain 
MRI (21).
B, Tanner breast stage.
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PP and PT was evaluated by constructing a receiver operating 
curve (ROC). Area under the curve (AUC) with 95% CIs were 
calculated from ROC. The cut-off value that maximizes sensitiv-
ity and specificity was selected. All tests were two-sided and the 
statistical significant level was set to P < 0.05.
resUlTs
The age-dependent etiologies of PP in girls are shown in Figure 2. 
In 6- to 8-year-old girls, the annual number of patients with PT 
increased during the study period (r =  0.6, P =  0.03), and the 
frequency of patients with PT showed similar trend but did not 
reach statistical significance (r = 0.5, P = 0.09). At the same time, 
the number of subjects with idiopathic GnRH-dependent PP 
remained constant (r = 0.2, P = 0.50). PT explained almost 70% 
of cases with PP aged less than 3 years (Figure 2). In the older 
girls (3–6 years of age), PT explained only 33% of cases with PP, 
whereas GnRH-dependent PP was now the most common etiol-
ogy (59%). In the latter age group, pathological GnRH-dependent 
PP was more frequent than the idiopathic form, and the frequency 
of pathologic GnRH-dependent PP was higher than in girls aged 
6–8  years (χ2  =  16.2, P  <  0.001). Overall, 67 (86%) girls with 
GnRH-dependent PP were treated with GnRH-analogs, includ-
ing all girls presenting signs of PP at age less than 6 years, 10 girls 
(83%) presenting at age 6–7 years, and 46 girls (83%) presenting 
at age 7–8 years. Of note, 17 girls were older than 8 years at the 
initiation of GnRH-analog treatment. The vast majority of cases 
with GnRH-independent PP (4 out of 5) were diagnosed prior 
to the age of 3 years. The etiology of GnRH-independent PP was 
McCune–Albright syndrome in four girls and an ovarian cyst in 
one girl.
A positive family history of PP was found in 38 (25%) girls: 
21 with idiopathic GnRH-dependent PP, 12 with PT, 3 with 
pathologic GnRH-dependent PP, and 3 with isolated menarche. 
Nineteen girls (13%) were adopted, of whom 15 had idiopathic 
GnRH-dependent PP, 3 had PT, and 1 had early menarche. None of 
the girls with PT had received the diagnoses of GnRH-dependent 
PP or early menarche after presenting with PT. Among the 6- to 
8-year-old girls with PT, the age at menarche was available for 11 
girls (31%). In all of them, menarche occurred within the normal 
limits for Finnish girls (5).
Brain Mri Findings
A brain MRI was performed in 56 girls with GnRH-dependent 
PP, including all girls younger than 6 years of age and in 45 out 
of 66 girls aged 6–8  years (Table  2). Fourteen girls (25%) had 
an abnormal brain MRI and the findings were as follows: a 
hamartoma in five, other tumor in two (e.g., astrocytoma, optic 
glioma), craniopharyngioma in one, partial agenesis of the cor-
pus callosum in one, hydrocephalus in one, pineal cyst in one, 
and other structural brain abnormalities unrelated to PP in three 
girls. Of the 14 abnormal MRI scans, five (three hamartomas, 
craniopharyngioma, and pineal cyst) were occult findings with-
out any prior symptoms, signs or predisposing disease (Table S1 
in Supplementary Material). Thus, the prevalence of an abnormal 
brain MRI in all girls without any predisposing disease was 
3.6% (5/139) (95% CI 1.6–8.9%), and that in girls with GnRH-
dependent PP was 6.4% (5/78) (95% CI 4.6–21.1%).
When the analysis was focused on the girls with GnRH-
dependent PP aged 6–8  years and no predisposing disease 
for PP, a brain MRI was performed in 41 (68%) subjects 
(Figure 1B). An abnormal MRI was found in two girls (3.3%, 
2/60) (95% CI 0.9–12.8%) (craniopharyngioma and pineal 
cyst) of which only the craniopharyngioma required immedi-
ate surgical treatment. Thus, in this subgroup, the prevalence 
of a CNS pathology requiring surgical intervention was 1.7% 
(1/60) (95% CI 0.3–9.7%), whereas it was 2.4% (1/41) (95% CI 
0.4–14.4%) in girls who were assessed with a brain MRI. In 
those not imaged (n = 19), GnRH-dependent PP was followed 
closely in the outpatient clinic, and none of the girls presented 
any symptoms or signs of a lesion in CNS during the follow-up. 
All except one of the girls not imaged were more than 7 years 
old at presentation, and the majority of the patients were 
considered by the treating physician to have either borderline 
TaBle 3 | Predictors of GnRH-dependent PP in girls (n = 96) who presented 
with signs of puberty between ages 6 and 8 years and had no predisposing 
disease for PP.
N n Or 95% ci P-value
Age (years) 96 60 0.8 0.3–1.8 0.6
Growth velocity (cm/year) 90 58 2.9 1.7–4.9 <0.001
Bone age advancement (years) 81 51 2.1 1.3–3.5 0.005
Family history of PP 88 52
No 57 31 1.0
Yes 31 21 1.3 0.6–4.0 0.3
Adoption 96 59
No 79 45 1.0
Yes 17 14 3.3 0.9–12.7 0.08
N, number of girls included in analysis; n, number of girls with GnRH dependent; PP, 
precocious puberty; OR, odds ratio; CI, confidence interval; GnRH, gonadotropin-
releasing hormone.
All analyses were adjusted with age.
TaBle 2 | MRI coverage in 78 girls with gonadotropin-releasing hormone-
dependent precocious puberty (PP) aged 0.7–8 years.
age (years) <3 3–6 6–7 7–8
Proportion of girls with  
brain MRI scan available
4/4 (100%) 7/7 (100%) 7/12 (58%) 39/55 (71%)
Abnormal findings in MRI 2/4 (50%) 5/7 (71%) 2/7 (29%) 5/39 (13%)
Patients are classified based on the age at presentation. Includes 10 girls with 
predisposing disease for PP.
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results in GnRH stimulation test (LH maximum 5–6  IU/L) 
or a feature that may increase the likelihood of idiopathic 
GnRH-dependent PP (adoption, positive family history of PP, 
or slow progression of puberty) or non-compliance to go to the 
scheduled brain MRI.
growth Velocity
In girls with PT (n  =  39), the annual growth velocity was 
lower (7.2 ±  1.2 cm/year) and the bone age was less advanced 
(1.3  ±  1.1  years) than in the girls with GnRH-dependent PP 
(n  =  71) (8.9  ±  2.3  cm/year, P  <  0.001 and 2.0  ±  0.9  years, 
P  <  0.001, respectively). The girls with GnRH-dependent PP 
had earlier age at take-off than the girls with PT (6.1  ±  1.4 vs 
7.1 ± 0.9 years, P = 0.02). Interestingly, in girls with pathologic 
GnRH-dependent PP, the age at take-off occurred at younger age 
than in girls with idiopathic GnRH-dependent PP (4.9 ± 1.9 vs 
6.4 ± 1.2 years, P = 0.003), but neither the growth velocity nor the 
advance in bone age differed from those with idiopathic GnRH-
dependent PP (Table S2 in Supplementary Material).
Six- to eight-year-olds with GnRH-dependent PP grew faster 
than those with PT (8.7 ± 2.0 cm/year, n = 58 vs 7.0 ± 1.1 cm/year, 
n = 32, P < 0.001) and had more advanced bone age (2.0 ± 0.9 
years, n = 51 vs 1.3 ± 1.1 years, n = 30, P = 0.002). Overall, growth 
velocity correlated positively with serum estradiol and GnRH-
stimulated LH levels (r = 0.32, P = 0.003 and r = 0.56, P < 0.001, 
respectively), and faster growth velocity also increased the odds 
of GnRH-dependent PP (Table  3). In ROC analysis, the best 
growth velocity cut-off value, 7.0  cm/year, discriminated girls 
with GnRH-dependent PP (n = 58) from those with PT (n = 32) 
with a sensitivity of 92% and a specificity of 58% (AUC 0.82, 95% 
CI 0.73–0.91, P  <  0.001). All girls with GnRH-dependent PP 
grew faster than 6  cm/year (sensitivity of 100% and specificity 
21%), and none of those with PT grew faster than 9.2 cm/year 
(sensitivity of 25% and specificity of 100%).
DiscUssiOn
We evaluated the etiology of PP in a large series of girls with a 
special focus on those aged 6–8 years, as their optimal manage-
ment has been debated (9, 12, 14, 27). The challenges in the 
diagnostic work-up of PP stem from several sources, as the 
timing of puberty shows complex interactions between genetic 
predisposition, nutritional status, general health, environmental 
hormone-like compounds, and stress (28–32). In previously 
healthy asymptomatic 6- to 8-year-old girls, the prevalence of an 
abnormal brain MRI was 3.3%, and the prevalence of abnormal 
MRI requiring surgical intervention was 1.7%. Among the 6- to 
8-year-olds, there were 19 girls who were not imaged, but none of 
them presented with signs of CNS processes during the follow-up 
which argues against significant CNS pathology. The 6.3-year-old 
girl with a craniopharyngioma had no prior symptoms or signs 
suggestive of a CNS lesion, and, thus, her diagnosis was expedited 
by current national clinical practice which recommends MRI 
imaging for girls who present with GnRH-dependent PP before 
the age of 8 years. Interestingly, this girl had a positive family his-
tory of PP, but overall in our cohort, the positive family history of 
early puberty was not a significant predictor of GnRH-dependent 
PP among 6- to 8-year-old girls. Recently, Giabicani et al. showed 
that girls evaluated for PP had more frequently pubertal LH/FSH 
ratio if they reported a family history of early puberty (33), but 
the study did not focus on girls aged 6–8 years.
The onset of breast development is the first sign of PP in girls. 
In obese girls, however, the presence of glandular breast tissue can 
be difficult to assess (12, 16), and if glandular tissue is present, the 
next task is to assess whether it is reactive due to increased estro-
gen levels or rather represents a local reaction of the hormone-
sensitive tissue to low amounts of circulating estrogens. In the 
presence of low estrogen levels and prepubertal LH response in 
the GnRH stimulation test, and exclusion of peripheral puberty 
and exogenous sources of estrogens, the condition is termed PT. 
Expectedly, PT was the most frequent cause of PP in girls younger 
than 3 years, but it also explained a significant proportion (more 
than one-third) of the cases in 6- to 8-year-old girls presenting 
with PP, which poses a diagnostic challenge. Between 2001 and 
2014, we found an increase in the number of girls diagnosed with 
PT but not in the frequency of girls with PT or with idiopathic 
GnRH-dependent PP, which may have resulted from the increased 
awareness of physicians referring girls with signs of PP, or from 
the possible influence of endocrine disruptors, or from a secular 
trend toward an earlier breast development. Supporting the latter, 
a recent Danish study reported a decline in the mean age of the 
appearance of glandular breast tissue without an earlier activa-
tion of the pituitary–gonadal axis (1). In our work, we defined 
PT as the presence of Tanner stage B2 before the age of 8 years, 
when the HPG axis was not activated according to the basal or 
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GnRH-stimulated LH levels. However, it is possible that some of 
our patients who presented with PT represent slowly progressing 
variants of CPP. Altogether these findings suggest that earlier 
breast development results in an increase in the proportion of 
girls with PT evaluated by pediatric endocrinologists. However, 
our results need to be validated in a larger population-based 
cohort.
Besides breast tissue, another clinically useful cue for estrogen 
action is growth velocity, a sensitive marker of exposure to estro-
gen (19, 34). Estrogen is known to accelerate growth directly and 
through increased growth hormone secretion (35–37). Our study 
included extensive growth measurements enabling a thorough 
evaluation of growth curves and an accurate identification of the 
age at take-off. Although obesity is known to accelerate growth 
in childhood, and an increase of one BMI unit is associated with 
a height gain of 0.29 cm in girls (38), our data shows that growth 
velocity prior to the evaluation of PP was a strong predictor for 
GnRH-dependent PP and could be used in the differential diag-
nosis between PT and PP within this age group. In fact, growth 
velocity cut-off level of 7.0 cm/year identified effectively GnRH-
dependent PP from PT in girls aged 6–8 years, and none of the 
girls with GnRH-dependent PP grew slower than 6 cm/year. In 
accordance with this finding, advanced bone age also emerged as 
a significant predictor of GnRH-dependent PP in 6- to 8-year-old 
girls. Although growth velocity overlapped between girls with PT 
and GnRH-dependent PP, the results validate the importance of 
careful evaluation of growth as part of the routine diagnostic 
process in girls with signs of early puberty.
The frequency of pathologic GnRH-dependent PP was 
more common in girls aged 3–6 years than in older girls. This 
is consistent with previous studies suggesting that young age 
clearly increases the risk of GnRH-dependent PP (8, 10, 39) 
and strongly supports the view that full diagnostic work-up, 
including brain MRI, is needed in this age group. The tendency 
toward an earlier onset of puberty is influenced by ethnicity. 
Furthermore, adopted girls are more likely to develop idiopathic 
GnRH-dependent PP than their native peers (7, 15), and in our 
series adoption increased the odds of GnRH-dependent PP with 
a borderline statistical significance.
While the main limitation of the study is its retrospective 
design, it should be noted that a prospective design is very 
difficult to conduct when describing the etiology of rare diseases 
such as PP (10, 18). Moreover, full diagnostic work-up of PP 
was not performed in all subjects, and, especially, 32% of 6- to 
8-year-old girls with GnRH-dependent PP did not have a brain 
MRI performed. However, these girls were followed up closely, 
and none of them presented with signs or symptoms of CNS 
pathology. Finally, our series included mainly Caucasian girls 
which should be taken into account when interpreting the results 
in countries with higher proportion of other ethnicities.
In conclusion, we found that the risk of GnRH-dependent PP 
is associated with growth velocity in 6- to 8-year-old girls. In this 
age group, the prevalence of abnormal MRI requiring interven-
tion in asymptomatic and previously healthy girls was low, but a 
lesion in CNS was present in one girl without any prior symptoms 
or signs. The results support the concept that brain MRI should 
be performed in girls with GnRH-dependent PP younger than 
8 years of age.
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